Abstract
BACKGROUND/AIM: This study aimed to identify potential drug associations between proteinuria and nephrotic syndrome (NS) using the Japanese Adverse Drug Event Report (JADER) database. PATIENTS AND METHODS: We extracted data reported in JADER between April 2004 and May 2023, and conducted a comprehensive disproportionality analysis of spontaneous adverse event reports to identify drugs potentially linked to proteinuria and NS. RESULTS: Our analysis identified 20 and 32 drugs associated with proteinuria and NS, respectively. Notably, anti-vascular endothelial growth factor (anti-VEGF) agents represented 45% (9/20) of proteinuria-associated drugs and 34% (11/32) of NS-associated drugs. Furthermore, the association between anti-VEGF agents and these adverse events appeared to be independent of the route of administration, sex, or clinical background. CONCLUSION: These findings suggest that anti-VEGF agents play a significant role in the development of proteinuria and NS. Given the widespread use of anti-VEGF therapy, heightened vigilance, routine monitoring, and timely interventions are crucial to mitigate these risks and improve patient outcomes.